Oncology
🇺🇸 FDA Page 16FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 181–192 of 246 articles
Inhibrx Biosciences to Present Ozekibart (INBRX-109) Clinical Data for Late-Line Colorectal Cancer Treatment
Akeso's Cadonilimab Shows Promising Survival Benefit in Advanced Pancreatic Cancer Phase II Trial
Debiopharm's Lunresertib Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer Treatment
Adcendo ApS Advances ADCE-T02 Antibody-Drug Conjugate to Expansion Phase, ADCE-D01 Receives FDA Orphan Drug Status
FDA Grants Priority Review to PADCEV-Keytruda Combination for Muscle-Invasive Bladder Cancer Treatment
FDA Project Frontrunner Initiative: What Companies Must Know
FDA Accelerated Approval Oncology: 2026 Trends & Market Access Impact
US Oncology Biosimilar Landscape 2026: Pricing & Market Access Insights
FDA Accelerated Approval Changes: Impact on Oncology Drug Development & Market Access 2026
ANVISA Guidelines for Antibody-Drug Conjugates: What You Need to Know
SAHPRA Accelerated Review Program: One Year Assessment & Oncology Approval Trends
Antibody-Drug Conjugates MEA: Pricing, Access & Adoption Insights 2024